Toll-like receptor 4-Myeloid differentiation factor 2 complex (TLR4-MD-2)

The Toll-like receptor 4-Myeloid differentiation factor 2 (TLR4-MD-2) complex is a fundamental component of the innate immune system, serving as the primary receptor for lipopolysaccharide (LPS) from Gram-negative bacteria (UniProt O00206, Q9Y6Y9). While TLR4 contains the transmembrane signaling domain, it cannot bind LPS directly and requires the extracellular protein MD-2 (LY96) to form a functional pocket for the lipid A moiety of the endotoxin (Kim et al., 2007, Cell). Upon ligand binding, the complex undergoes a conformational change that leads to the dimerization of two TLR4-MD-2-LPS units, which subsequently activates intracellular signaling via the MyD88 and TRIF pathways (Park et al., 2009, Nature). This activation triggers the production of pro-inflammatory cytokines and interferons necessary for host defense. However, over-activation of this complex is a central driver of the systemic inflammatory response seen in sepsis and various chronic inflammatory diseases (Ciesielska et al., 2021, Molecular Cancer). Consequently, the TLR4-MD-2 complex is a major therapeutic target for both antagonists aimed at treating inflammatory shock and agonists used as potent vaccine adjuvants (Rice et al., 2010, Critical Care Medicine).

Other names

TLR4-LY96 complexCD284-MD2 complexToll-like receptor 4-Lymphocyte antigen 96 complexLPS receptor complexTLR4/MD2 heterodimer

Antagonists typically function by competitively binding to the MD-2 hydrophobic pocket to block lipopolysaccharide (LPS) docking or by binding to the TLR4 intracellular domain to prevent the recruitment of adapter proteins like MyD88 and TRIF. Agonists, such as MPLA, mimic the lipid A portion of LPS to induce controlled receptor dimerization and immune activation for use as vaccine adjuvants (Park et al., 2009, Nature; O'Neill et al., 2013, Nature Reviews Immunology).